Skip to content
DataLookout
Menu

MyVisionXTNCT07465289

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved 53 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 7 → 18 locations
  2. Minor Primary and study completion pushed from Jan 23, 2031 to Mar 17, 2031
    • Eligibility criteria shortened, about 1 word
  3. Minor Eligibility criteria expanded, about 1 word
  4. Notable Recruitment opened
    • Eligibility criteria expanded, about 14 words
    • Trial sites expanded: 0 → 7 locations
    • Secondary endpoints: details revised at 6 of 7 entries
  5. Notable Start date: Jul 27, 2026 to Sep 16, 2026v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of treatment-emergent adverse events (TEAEs)
Timeframe: Up to 2 years
Incidence of treatment-emergent serious adverse events (TESAEs)
Timeframe: Up to 2 years
Incidence of TEAEs leading to permanent withdrawal of study treatment
Timeframe: Up to 2 years

Secondary (7)

Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome part)
Change from Baseline at Day 43 in Myasthenia Gravis Activities of Daily Living (MG-ADL) ocular score
Change from Baseline at Day 43 in Myasthenia Gravis Symptoms Patient-Reported Outcome (MGSPRO) ocular muscle weakness scale score
Change from Baseline at Day 43 in Myasthenia Gravis Quality of Life 15-item Scale (revised version) (MG-QoL15r) total score
Study participant who generalizes to Myasthenia Gravis Foundation of America (MGFA) class ≥2 over time
Show 2 moreShow less
Change from Baseline in MGII total and generalized score over time
Change from Baseline in MG-ADL total score over time

Arms and interventions

RozanolixizumabExperimental

The study is composed of Extended Observation Period(s) and Symptom-driven Cycle(s). Based on their clinical need for treatment, study participants will be able to start the study with either an Extended Observation Period or a Symptom-driven Cycle. A Symptom-driven Cycle will be initiated based on disease worsening and participants will receive rozanolixizumab based on investigator's medical judgement.

Drugs: Rozanolixizumab

Sites

18 sites in 7 countries

China 5, Spain 4, Japan 3, Georgia 2, United States 2, France 1, Poland 1